Published in Oncologist on June 28, 2013
Ponatinib in Advanced NSCLC w/ RET Translocations | NCT01813734
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res (2015) 1.29
The evolving genomic classification of lung cancer. J Pathol (2014) 1.08
Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clin Lung Cancer (2013) 1.01
High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer. Ann Oncol (2015) 0.99
New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs. Clin Cancer Res (2014) 0.90
Epidemiology of Lung Cancer in Korea: Recent Trends. Tuberc Respir Dis (Seoul) (2016) 0.88
Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer. Int J Clin Exp Med (2015) 0.86
Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR. PLoS One (2015) 0.84
Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway. Oncotarget (2016) 0.83
Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch (2016) 0.83
The prognostic role of intragenic copy number breakpoints and identification of novel fusion genes in paediatric high grade glioma. Acta Neuropathol Commun (2014) 0.82
Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma. Mol Cancer Ther (2016) 0.82
Efficient generation and reversion of chromosomal translocations using CRISPR/Cas technology. BMC Genomics (2016) 0.80
Tripartite motif-containing 29 as a novel biomarker in non-small cell lung cancer. Oncol Lett (2015) 0.77
Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site. Cancer Biol Ther (2016) 0.76
Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells. Neoplasia (2016) 0.76
A Histopathological Feature of EGFR-Mutated Lung Adenocarcinomas with Highly Malignant Potential - An Implication of Micropapillary Element. PLoS One (2016) 0.75
Dimethylarginine dimethylaminohydrolase 2 promotes tumor angiogenesis in lung adenocarcinoma. Virchows Arch (2015) 0.75
Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target. Histopathology (2016) 0.75
Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement. BMC Cancer (2016) 0.75
Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis. Oncotarget (2016) 0.75
ROS1 copy number alterations are frequent in non-small cell lung cancer. Oncotarget (2016) 0.75
Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer. Clin Cancer Res (2016) 0.75
KAOS: a new automated computational method for the identification of overexpressed genes. BMC Bioinformatics (2016) 0.75
The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis. Cancer Biol Ther (2015) 0.75
Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors. Transl Lung Cancer Res (2016) 0.75
Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies. Oncotarget (2017) 0.75
Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer. Front Oncol (2017) 0.75
Recent Advances in Targeting ROS1 in Lung Cancer. J Thorac Oncol (2017) 0.75
Lung cancer as a paradigm for precision oncology in solid tumours. Virchows Arch (2017) 0.75
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci U S A (2002) 25.47
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell (2007) 17.98
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer (2007) 9.81
ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 7.65
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med (2012) 6.77
RET, ROS1 and ALK fusions in lung cancer. Nat Med (2012) 6.76
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res (2008) 6.71
Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell (2012) 6.09
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature (1993) 5.81
Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature (1994) 5.61
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet (1993) 4.38
KIF5B-RET fusions in lung adenocarcinoma. Nat Med (2012) 4.38
A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res (2011) 4.15
PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell (1990) 3.98
Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell (1985) 3.86
Defects in enteric innervation and kidney development in mice lacking GDNF. Nature (1996) 3.82
The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res (2012) 3.80
RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol (2012) 3.72
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov (2013) 3.64
Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature (1994) 3.46
Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature (1994) 3.33
EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol (2009) 3.15
Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One (2011) 3.10
GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell (1996) 2.86
Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer (2003) 2.67
Chipping away at the lung cancer genome. Nat Med (2012) 2.67
Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res (2012) 2.66
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol (2008) 2.59
Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res (2012) 2.53
Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A (1994) 2.25
GDNF signalling through the Ret receptor tyrosine kinase. Nature (1996) 2.21
Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One (2011) 2.17
Human ret proto-oncogene mapped to chromosome 10q11.2. Oncogene (1989) 2.17
Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci U S A (1987) 2.11
Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature (1996) 2.09
Characterization of an activated human ros gene. Mol Cell Biol (1986) 1.97
Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene (1988) 1.95
Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a transmembrane receptorlike molecule. Mol Cell Biol (1986) 1.89
ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res (2006) 1.80
The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta (2008) 1.77
Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol (2012) 1.76
Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.71
RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose. Cancer Res (2008) 1.67
Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol (2012) 1.66
Targeting the RET pathway in thyroid cancer. Clin Cancer Res (2009) 1.62
Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res (2012) 1.56
Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours. PLoS One (2011) 1.53
ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol (2013) 1.52
Mutation-associated fusion cancer genes in solid tumors. Mol Cancer Ther (2009) 1.45
Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer (2013) 1.43
The c-ros tyrosine kinase receptor controls regionalization and differentiation of epithelial cells in the epididymis. Genes Dev (1996) 1.39
RET proto-oncogene in the development of human cancer. J Clin Oncol (1999) 1.38
A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J Thorac Oncol (2013) 1.37
Crizotinib and testing for ALK. J Natl Compr Canc Netw (2011) 1.35
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer (2009) 1.33
Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma. Proc Natl Acad Sci U S A (2003) 1.33
Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res (2010) 1.32
Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) (1996) 1.31
RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol (2006) 1.29
Activated RET oncogene in thyroid cancers of children from areas contaminated by Chernobyl accident. Lancet (1994) 1.25
Association of a novel PDZ domain-containing peripheral Golgi protein with the Q-SNARE (Q-soluble N-ethylmaleimide-sensitive fusion protein (NSF) attachment protein receptor) protein syntaxin 6. J Biol Chem (2001) 1.23
Completing the Arc: targeted inhibition of RET in medullary thyroid cancer. J Clin Oncol (2011) 1.19
Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad. J Thorac Oncol (2012) 1.18
Transient and locally restricted expression of the ros1 protooncogene during mouse development. EMBO J (1991) 1.14
The human c-ros gene (ROS) is located at chromosome region 6q16----6q22. Proc Natl Acad Sci U S A (1986) 1.12
The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation. Cancer Res (2012) 1.10
RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint. Eur J Endocrinol (2011) 1.10
A high-dimensional, deep-sequencing study of lung adenocarcinoma in female never-smokers. PLoS One (2013) 1.08
Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. J Thorac Oncol (2012) 1.06
Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab (1996) 1.02
Characterization of the ros1-gene products expressed in human glioblastoma cell lines. Oncogene Res (1989) 1.01
Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. Nat Clin Pract Oncol (2006) 1.01
ROS receptor tyrosine kinase: a new potential target for anticancer drugs. Med Res Rev (2010) 1.01
Expression of the ret proto-oncogene product in human normal and neoplastic tissues of neural crest origin. J Pathol (1994) 0.97
KIF5B-RET fusions in Chinese patients with non-small cell lung cancer. Cancer (2013) 0.97
Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers. Cell Res (2012) 0.96
KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung. Oncol Rep (2012) 0.95
ROS1 rearrangements in lung cancer: a new genomic subset of lung adenocarcinoma. J Clin Oncol (2012) 0.95
c-ros: the vertebrate homolog of the sevenless tyrosine kinase receptor is tightly regulated during organogenesis in mouse embryonic development. Development (1992) 0.92
Zeroing in on ROS1 rearrangements in non-small cell lung cancer. Clin Cancer Res (2012) 0.91
Structure and physiology of the RET receptor tyrosine kinase. Cold Spring Harb Perspect Biol (2013) 0.90
Mouse model for ROS1-rearranged lung cancer. PLoS One (2013) 0.88
RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer. Cancer Med (2012) 0.85
RET fusion genes in non-small-cell lung cancer. J Clin Oncol (2012) 0.84
Oncogenic rearrangements of the ret proto-oncogene in thyroid tumors induced after exposure to ionizing radiation. Biochimie (1997) 0.81
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94
ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med (2012) 8.41
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (2004) 8.16
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol (2012) 5.16
Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med (2013) 4.74
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A (2011) 3.97
Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med (2013) 3.42
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res (2013) 2.65
Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol (2013) 1.88
The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. J Thorac Oncol (2013) 1.82
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov (2013) 1.63
Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol (2015) 1.50
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol (2010) 1.31
Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 1.28
Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin Cancer Res (2014) 1.21
A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. J Thorac Oncol (2012) 1.11
Crizotinib. Nat Rev Drug Discov (2011) 1.05
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2015) 0.97
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol (2015) 0.97
New targets in advanced NSCLC: EML4-ALK. Clin Adv Hematol Oncol (2011) 0.93
Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med (2013) 0.92
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol (2015) 0.84
Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer. J Thorac Oncol (2014) 0.82
Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib. J Thorac Oncol (2014) 0.81
Hypogonadism related to crizotinib therapy: implications for patient care. Cancer (2012) 0.80
Are anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer prognostic, predictive, or both? J Thorac Oncol (2012) 0.78
The new kid on the block: RET in lung cancer. Cancer Discov (2013) 0.77
Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer? Clin Cancer Res (2012) 0.77
A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis. J Immunother (2017) 0.76
One allele's loss is another's gain: alterations of NKX2-8 in non-small cell lung cancer. Clin Cancer Res (2010) 0.75
Crizotinib Resensitization by Compound Mutation. N Engl J Med (2016) 0.75
Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife (2017) 0.75